Want to see CYAN full AI Analyst Report?
CYAN Stock Chart & Stats
$0.53
$0.00(0.00%)
At close: 4:00 PM EDT
$0.53
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.23 - $0.57
Previous CloseN/A
Volume60.00
Average Volume (3M)6.46K
Market Cap
$3.62M
Enterprise Value$12.96
Total Cash (Recent Filing)$1.09M
Total Debt (Recent Filing)$11.37M
Price to Earnings (P/E)―
Beta0.03
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding7,392,243
10 Day Avg. Volume1,585
30 Day Avg. Volume6,463
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.28
Price to Sales (P/S)0.10
P/FCF Ratio-1.72
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Vertically Integrated Microalgae ProductionCyanotech's vertically integrated large-scale cultivation and manufacture of spirulina and astaxanthin supports durable competitive advantages: specialized production assets, processing know‑how, and exposure to both consumer and B2B channels. These create barriers to entry and steady demand.
Revenue StabilizationTwo consecutive years of modest revenue growth (+5% in 2025 and +5% in 2026) indicate stabilization after prior weakness. Persistent top‑line improvement supports better capacity utilization and incremental margin gains, making sustainable operating leverage more attainable over the next several quarters.
Margin Recovery & Positive EBITDAGross margin rebounded to ~33% and EBITDA turned positive in 2026, signaling improved pricing and cost management. Positive EBITDA demonstrates the core business can generate operating cash before depreciation and interest, a key milestone toward durable profitability if management continues to address fixed costs.
Bears Say
Rising LeverageDebt-to-equity rising to ~1.51 from ~0.46 since 2022 reflects materially higher leverage and an eroded equity base. Elevated leverage reduces financial flexibility, raises refinancing and interest-rate risk, and constrains the company’s ability to invest or absorb another earnings setback.
Fragile Cash GenerationOperating cash flow only turned slightly positive (~$0.2M) and free cash flow was marginal (~$0.1M) in 2026 after multi-year volatility. Such limited, brittle cash generation restricts internal funding for maintenance and growth capex, forcing reliance on external financing and increasing liquidity risk.
Ongoing Net And Operating LossesDespite improvement, the company remained loss-making in 2026 with a net loss of ~ $1.3M and negative operating income. Persistent losses erode shareholder equity, necessitate external capital to fund operations, and mean the firm has not yet demonstrated durable earnings stability.
Cyanotech News
CYAN FAQ
What was Cyanotech’s price range in the past 12 months?
Cyanotech lowest stock price was $0.23 and its highest was $0.57 in the past 12 months.
What is Cyanotech’s market cap?
Cyanotech’s market cap is $3.62M.
When is Cyanotech’s upcoming earnings report date?
Cyanotech’s upcoming earnings report date is Nov 18, 2026 which is in 91 days.
How were Cyanotech’s earnings last quarter?
Currently, no data Available
Is Cyanotech overvalued?
According to Wall Street analysts Cyanotech’s price is currently Overvalued.
Does Cyanotech pay dividends?
Cyanotech does not currently pay dividends.
What is Cyanotech’s EPS estimate?
Cyanotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cyanotech have?
Cyanotech has 7,392,243 shares outstanding.
What happened to Cyanotech’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cyanotech?
Currently, no hedge funds are holding shares in CYAN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cyanotech
Established in 1983 and headquartered in Kailua-Kona, Hawaii, Cyanotech Corporation specializes in the global cultivation, processing, and distribution of natural products derived from microalgae. Its key product offerings include BioAstin Hawaiian Astaxanthin, a powerful dietary antioxidant acclaimed for promoting skin health and supporting eye, joint, and immune system functions; it is utilized as both a dietary supplement and an ingredient. Another significant product is Hawaiian Spirulina Pacifica, a highly nutritious dietary supplement formulated to enhance energy levels, bolster the immune system, provide cardiovascular benefits, and deliver a rich source of antioxidant carotenoids. Beyond its product lines, Cyanotech also offers contract extraction services. The company reaches its customers through a diverse array of sales channels, encompassing third-party distributors, retailers, and online platforms, as well as direct sales to consumers. Additionally, it supplies products in bulk to manufacturers, formulators, and distributors within the health foods, nutraceuticals, and dietary supplement industries.
Technical Analysis
Nature's Sunshine Products
―
Seneca Foods
―
Hain Celestial
―
USANA Health
―
Laird Superfood
―